Embla Medical Hf S/Adr (OSSUY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to EMPLA Medical Q1 2026 conference call. Today's call is being recorded. If you have any objections to this, please disconnect your line. All participants will be in a listen-only mode throughout the presentation. And afterwards, there will be a question and answer session. To ask a question, please press 5 star on your telephone keypad. I would like to introduce President and CEO, Sven Silverson. and CFO Arne Svensdottir. Sven, please begin. Thank you very much. Good morning, and welcome to the AmpliMedical conference call, where we will review the first quarter results for 2026. I'm Fred Salvestrøm, President and CEO of AmpliMedical, and joining me on today's call is our Chief Financial Officer, Arne Svensdottir, and AmpliMedical's Head of Investor Relations, Carl Sindahl. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session. Now, if you would please go to the next slide. We are seeing good progress at the beginning of 2026. Sales in the first quarter amounted to 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in prosthetics and neuro-orthotics, driven by continued momentum and solid volume growth across reasons and categories. Growth in rating and support was moderate, and patient care experience was off course, largely driven by timing effects in Europe. Our EBITDA margin for the quarter came in at 17%, and is down one percentage point from the comparable quarter last year, largely due to external factors such as effects and tariffs. We delivered strong net profit, growth driven by growing operating results and favorable changes in net financial expenses. During the first quarter, we continued to roll out of our prom...